3 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Approved WMORecruiting
To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL).
Approved WMOPending
This is a research study. The purpose of this study is to test if the investigational medicinal product S48168 (ARM210) is safe and effective when given to patients diagnosed with CPVT1. Primairy objective:To assess the effect of S48168 (ARM210) on…